Cerebral venous thrombosis (CVT) presenting as subarachnoid hemorrhage (SAH) is infrequent. We present a man with CVT of right transverse sinus who presented a SAH in right parietal sinus. In the study we found a hyperhomocysteinemia in a heterozygous patient for the methylenetetrahydrofolate reductase C667T mutation. Our report highlights the value of an early diagnosis of CVT, the importance to identify possible causes that could be reversed with an appropriate treatment and the controversy about the moment of starting anticoagulant therapy in such cases.
INTRODUCTION
Cerebral venous thrombosis (CVT) is an increasing disease in daily practice with sharing clinical nonspecific symptoms. This disorder is more often associated with acute-onset headache of severe intensity presenting in up to 77% in some studies 1 . However, CVT presenting with an associated subarachnoid hemorrhage (SAH) on computed tomography (CT) and magnetic resonance (MR) is as infrequent 2, 3 as more and more recognized as potential complication of CVT.
On the other hand, high levels of homocysteine are a known risk factor for venous and arterial thrombosis. However, its role in stroke remains controversial and a positive association between homocysteine and stroke has not been established in some nested casecontrol studies 4 .
We present the case of a patient with thrombosis in the right transverse sinus with SAH associated. We describe the imaging and laboratory findings regarding high levels of homocysteine as a potential etiology in this case. Finally we discuss about the treatment chosen and the management of CVT with SAH.
CASE REPORT
A 70-year old man with progressive occipital headache, and nausea was admitted to our ward. He had clinical history of hypertension which was being treated with ramipril 5 mg and cobalamine were normal: 5.9 ngr/ml (normal values between 3 and 17 ng/ml) and 169 pgr/ml (normal values between 211 and 911 pgr/ml) respectively. We later found the patient was heterozygous for the methylenetetrahydrofolate reductase C667T mutations.
We began treatment with ordinary care. Low-molecular weight heparin, 60 mg once a day, was initiated from admission. The third day after admission we raised dose to 120mg at day for a week, then, the patient started oral anticoagulation after no evidence of worsening of SAH.
DISCUSSION
CVT is responsible for 1-2% of all strokes in adults 5 , but isolated CVT (without sinus involvement) appears very rare. Furthermore, CVT is a potential cause of cortical SAH.
Panda et al 6 . reported that ten of 233 patients with CVT had evidence of cortical SAH, and
Oda et al 7 . found 3% of SAH caused by CVT, indicating that the presence of cortical SAH without involvement of the basal cisterns may provide an early sign of underlying CVT.
However, what is more interesting in this case, is the relationship of high levels of plasma homocysteine with CVT and SAH previously undescribed. There is broad epidemiological evidence to correlate elevated levels of homocysteine with increased risk of thromboembolic events 8, 9 , however, most studies have been case-control for which blood samples drawn to measure homocysteine, were collected after the event.
The methylenetetrahydrofolate reductase (MTHFR) gene polymorphism introduced another means of testing the hypothesis of causality between homocysteine levels and venous thrombosis, however, an association between MTHFR gene mutations and venous thrombosis has not been found by different studies 10, 11 and, regarding CVT, recent publications showed a relationship with increased levels of homocysteine but not with MTHFR gene mutations 12, 13 . The current hypothesis is that MTHFR gene mutations (both, 677TT and 677CT) raise plasma levels of homocysteine which produce increasing risk for cardiovascular events and that the level of hyperhomocysteine to induce endothelial dysfunction in cerebral vessels is lower than the level needed to produce the same alteration in the systemic circulation 14 .
The distribution of SAH associated with CVT is usually different from that of SAH of arterial origin, which has a characteristic pattern, in fact, when SAH is localized at the cerebral convexity and spares the basal cisterns and skull base, CVT should be considered 6 .
The exact mechanism of cortical SAH, caused by CVT is unknown. One possibility is the rupture of venous parenchymal hemorrhagic infarcts into the subarachnoid space 15, 16 though findings of hemorrhagic venous infarction were not found in our patient. Another possible mechanism is venous hypertension and subsequent rupture of dilated valueless, thin-walled bridging subarachnoid cortical veins devoid of smooth muscle fibers 15 . This doi:10.3121/cmr.2014.1225
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Finally a third mechanism of development of SAH could be a local inflammatory response caused by CVT, which would increase the vascular permeability allowing for extravasation of blood into the subarachnoid space. This mechanism also could have been present, in our patient who had proinflammatory status because of his altered metabolism of homocysteine. In fact, hyperhomocysteinemia is thought to lead to endothelial dysfunction probably produced by reduction in the availability of nitric oxide 17 and to an increase of the oxidative stress with alteration of the redox state of the endothelium 18 .
Management of SAH secondary to CVT is quite different from that of arterial SAH. The usual treatment of sinus thrombosis is anticoagulation or local thrombolysis. Systemic anticoagulation is the first line treatment for cerebral venous thrombosis because of its efficacy, safety and feasibility 19 . In a further placebo-controlled trial, 60 patients were randomized to either lower molecular weight heparin followed by warfarin or placebo 20 .
The anticoagulated patients had better outcomes than controls, but the difference was not statistically significant. The investigators suggested that anticoagulation was safe, even in patients with cerebral hemorrhage 19 . However, the present case was not an intraparenchymal hemorrhage but a SAH. We considered that intravenous heparin would deteriorate SAH and preferred to initiate low doses of fractionated heparin, 60 mg once a day, then, on the third day we raised doses to 120 mg at day for a week. On the second week oral anticoagulation was started after no evidence of worsening of SAH.
Anticoagulation had not started so early in other cases reported 7 because of high risk of
